GAEA Pharma UK

Gaea began in 1994 and supports US companies running clinical trials in the EU, as they often find start-up and acceleration difficult in this area.

The director, Nigel Goodman describes the background and thinking of Gaea:

“I set up Gaea with the experience I gained in the Amgen-Roche Venture Team.

Our team had found that by using a validated product profile we could reduce the time taken to move drugs through clinical development to regulatory submission. There has been significant progress in this clinical development, but there is still a lot to achieve. Gaea provides the services of product concept testing and market assessment; the key question being – is there a market worth pursuing?


We offer to help with an effective study start up because a slow start up can reduce morale and the longer a study takes the more it costs in CRO fees.

For ongoing studies, we will work on clinical trial sites of concern, in conjunction with the CRO, to define those issues that are delaying enrolment and to offer solutions. The emphasis of these solutions will be on practical activities to solve the issues and accelerate the enrolment or, if necessary, to recommend closing the site. This can be necessary because non-productive sites cost money in CRO fees.We also provide regulatory advice and actions in the EU. We offer input on pricing and reimbursement and their implications.Gaea, or Mother Earth, was the great goddess of the early Greeks and She represented the Earth.

In the creation story of the early Greeks, before the creation of the Universe there was Chaos. Chaos was made of Void, Mass and Darkness in confusion. Then Earth, in the form of Gaea, came into existence. Back in 1994 when I set up Gaea there was plenty of CHAOS in development and so a consultancy with the name Gaea was appropriate.